BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-01
193 industry Phase 2/3 trial readout(s) and 29 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-01 est. | P1/P2 | US Oncology Research | NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | Breast Neoplasms; Malignant Neoplasm of Breast | active not recruiting | 34 |
| 2025-01 est. | P2 | Allievex Corporation | NCT03784287 A Treatment Extension Study of Mucopolysaccharidosis Type IIIB | Mucopolysaccharidosis Type IIIB; MPS III B | unknown | 20 |
| 2025-01 est. | P3 | Advicenne Pharma | NCT03831152 Extension Study in Primary Distal Renal Tubular Acidosis | Acidosis, Renal Tubular | withdrawn | |
| 2025-01 est. | P3 | Dr. Falk Pharma GmbH | NCT03872921 norUrsodeoxycholic Acid vs Placebo in PSC | Primary Sclerosing Cholangitis | unknown | 303 |
| 2025-01 est. | P2 | RedHill Biopharma Limited RDHL | NCT04027894 Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years | Traveler's Diarrhea | unknown | 142 |
| 2025-01 est. | P2 | Andover Eye Associates | NCT04296864 Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC) | Atopic Keratoconjunctivitis | unknown | 42 |
| 2025-01 est. | P3 | EMS | NCT04970108 Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension | Hypertension Associated; Type II Diabetes Mellitus | withdrawn | |
| 2025-01 est. | P2 | Dr. Falk Pharma GmbH | NCT05083390 Norursodeoxycholic Acid vs. Placebo in NASH | Nonalcoholic Steatohepatitis | unknown | 363 |
| 2025-01 est. | P2 | R-Pharm International, LLC | NCT05092776 Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Into | Familial Mediterranean Fever; FMF | active not recruiting | 84 |
| 2025-01 est. | P1/P2 | Nuvation Bio Inc. NUVB | NCT05191017 Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Prostate Cancer; Prostatic Cancer; Cancer of Prostate; Cancer of the Prostate; Prostate Neoplasm; Ca | withdrawn | |
| 2025-01 est. | P3 | Moberg Pharma AB | NCT05279846 A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) | Onychomycosis | unknown | 350 |
| 2025-01 est. | P1/P2 | Shanghai Vitalgen BioPharma Co., Ltd. | NCT05441553 A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients | Hemophilia B | unknown | 26 |
| 2025-01 est. | P3 | EMS | NCT05456152 Safety and Efficacy of Zolpidem in the Long-Term Treatment of Insomnia | Chronic Insomnia | unknown | 358 |
| 2025-01 est. | P2 | Shanton Pharma Pte. Ltd. | NCT05690204 Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. | Gout | active not recruiting | 87 |
| 2025-01 est. | P3 | Biocad | NCT05730699 Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) | Neuromyelitis Optica Spectrum Disorders | active not recruiting | 105 |
| 2025-01 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05774340 A Study of CM326 in Subjects With Moderate to Severe Asthma | Moderate to Severe Asthma | unknown | 207 |
| 2025-01 est. | P3 | ReFlow Medical, Inc. | NCT05848232 Single-Arm Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total Occlusions | Coronary Occlusion | unknown | 150 |
| 2025-01 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06121830 Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD) | Non-erosive Reflux Disease; Non-Erosive Gastro-Esophageal Reflux Disease; Non-Erosive Esophageal Ref | unknown | 324 |
| 2025-01 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06279286 Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder | Insomnia Disorder | unknown | 312 |
| 2025-01 est. | P3 | Biocad | NCT06296121 A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | unknown | 252 |
| 2025-01 est. | P2 | Luye Pharma Group Ltd. | NCT06467409 Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery | Pain, Postoperative | unknown | 150 |
| 2025-01-01 est. | P3 | Zai Lab (Hong Kong), Ltd. | NCT06162286 A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP | Community-acquired Bacterial Pneumonia | unknown | 100 |
| 2025-01-01 | P1/P2 | Valerio Therapeutics | NCT06257758 A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Advanced or Metastatic Solid Tumors; Breast Cancer; Recurrent Ovarian Cancer; Prostate Cancer | terminated | 6 |
| 2025-01-01 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06516094 Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain | Chronic Low-back Pain | completed | 192 |
| 2025-01-02 | P3 | Vor Biopharma VOR | NCT06456567 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) | Systemic Lupus Erythematosus | withdrawn | |
| 2025-01-02 | P2 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NCT06545500 A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD | Chronic Obstructive Pulmonary Disease | completed | 46 |
| 2025-01-03 | P1/P2 | Sun Pharma Advanced Research Company Limited | NCT02629692 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | Healthy (For Part A); Chronic Myeloid Leukemia (for Part B and C) | terminated | 124 |
| 2025-01-03 | P2 | Boehringer Ingelheim | NCT05213624 A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis | Kidney Disease, Chronic | completed | 67 |
| 2025-01-03 | P2 | Chipscreen Biosciences, Ltd. | NCT05497843 Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | Soft Tissue Sarcoma | completed | 40 |
| 2025-01-03 | P2 | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | NCT06001177 A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease | Celiac Disease; Coeliac Disease | completed | 55 |
| 2025-01-03 | P1/P2 | Immunwork, Inc. | NCT06471530 A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes | Overweight and Obesity | completed | 38 |
| 2025-01-03 | P1/P2 | Metsera, a wholly owned subsidiary of Pfizer | NCT06857617 This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity | Obesity and Overweight | completed | 120 |
| 2025-01-04 | P3 | Bharat Biotech International Limited | NCT06200844 The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants | Rotavirus Infection of Children | active not recruiting | 5800 |
| 2025-01-04 | P2 | Response Pharmaceuticals | NCT06640972 Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated | completed | 68 |
| 2025-01-06 | P1/P2 | Takeda TAK | NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Pancreatic Cancer; Hepatocellular Cancer; Mesothelioma; Breast Cancer; Gastric Cancer; Esophageal Ca | terminated | 61 |
| 2025-01-06 | P3 | Vor Biopharma VOR | NCT05306574 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) | Systemic Lupus Erythematosus | terminated | 91 |
| 2025-01-06 | P2 | Trevi Therapeutics TRVI | NCT05962151 Refractory Chronic Cough Improvement Via NAL ER (RIVER) | Refractory Chronic Cough | completed | 66 |
| 2025-01-06 | P1/P2 | Daiichi Sankyo | NCT05979831 A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome | Netherton Syndrome | terminated | 9 |
| 2025-01-06 | P3 | Novo Nordisk A/S NVO | NCT05996848 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight | Obesity or Overweight | completed | 300 |
| 2025-01-06 | P3 | Shanghai Ark Biopharmaceutical Co., Ltd. | NCT06359899 A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD | ADHD | completed | 55 |
| 2025-01-07 | P1/P2 | Medivir | NCT03781934 A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases | completed | 53 |
| 2025-01-07 | P1/P2 | Advanced Accelerator Applications | NCT03872778 [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake | Neoplasms | completed | 35 |
| 2025-01-07 | P3 | Merck Sharp & Dohme LLC MRK | NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG | Uterine Cervical Neoplasms | completed | 1060 |
| 2025-01-07 | P3 | Janssen Research & Development, LLC | NCT04497844 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Del | Prostatic Neoplasms | active not recruiting | 696 |
| 2025-01-07 | P1/P2 | Kronos Bio | NCT04718675 A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | Relapsed Solid Tumors; Refractory Solid Tumors; Non-Hodgkin Lymphoma; HGSOC; Platinum Resistant High | terminated | 135 |
| 2025-01-07 est. | P2 | Immunic AG IMUX | NCT05054140 Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis | Multiple Sclerosis | unknown | 450 |
| 2025-01-07 | P3 | Incyte Corporation INCY | NCT05620836 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Hidradenitis Suppurativa (HS) | completed | 619 |
| 2025-01-08 | P1/P2 | BioAtla, Inc. BCAB | NCT03425279 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma | completed | 245 |
| 2025-01-08 | P3 | Amgen AMGN | NCT03832998 Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | Migraine | completed | 284 |
| 2025-01-08 | P3 | BeiGene | NCT03957590 A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamou | Esophageal Squamous Cell Carcinoma (ESCC) | completed | 370 |
| 2025-01-08 | P1/P2 | Ultragenyx Pharmaceutical Inc RARE | NCT04259281 A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome | Angelman Syndrome | completed | 74 |
| 2025-01-08 | P3 | Mural Oncology, Inc | NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | terminated | 456 |
| 2025-01-08 est. | P2/P3 | SMT bio Co., Ltd. | NCT05429697 Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | unknown | 128 |
| 2025-01-08 est. | P3 | Azidus Brasil | NCT06089122 Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG | Primary Immunodeficiency Disease | unknown | 50 |
| 2025-01-08 | P1/P2 | Norroy Bioscience Co., LTD | NCT06389682 Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients | Clear Cell Renal Cell Carcinoma Metastatic | completed | 19 |
| 2025-01-09 | P1/P2 | Constellation Pharmaceuticals CEG | NCT02158858 A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | Myelofibrosis; Leukemia, Myelocytic, Acute; Myelodysplastic/Myeloproliferative Neoplasm; Myelodyspla | completed | 336 |
| 2025-01-09 | P2/P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT03651765 Long Term Extension Trial of Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | 205 |
| 2025-01-09 | P1/P2 | Hookipa Biotech GmbH | NCT04180215 A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers | HPV-Related Squamous Cell Carcinoma | completed | 198 |
| 2025-01-09 | P1/P2 | Lyell Immunopharma, Inc. LYEL | NCT06153095 A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus; Lupus Nephritis | withdrawn | |
| 2025-01-09 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06525506 A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease | Thyroid Eye Disease | completed | 38 |
| 2025-01-09 est. | P1/P2 | Intellia Therapeutics NTLA | NCT06622668 NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease | Lung Disease; Pulmonary Disease; AATD; Alpha-1 Antitrypsin Deficiency; Alpha-1 Antitrypsin Deficienc | withdrawn | |
| 2025-01-10 | P2 | ChemomAb Ltd. CMMB | NCT04595825 CM-101 in PSC Patients -The SPRING Study | Primary Sclerosing Cholangitis | completed | 77 |
| 2025-01-10 | P2 | NovoCure GmbH NVCR | NCT04892472 EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of | Non-small Cell Lung Cancer | terminated | 15 |
| 2025-01-10 | P1/P2 | LaNova Medicines Zhejiang Co., Ltd. | NCT05161390 Study of LM-302 in Patients With Advance Solid Tumors | Advanced Solid Tumor | completed | 153 |
| 2025-01-10 | P3 | Immunovant Sciences GmbH IMVT | NCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | terminated | 233 |
| 2025-01-10 | P1/P2 | Shanxi Kangbao Biological Product Co., Ltd. | NCT06560489 Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients | Hiv | completed | 40 |
| 2025-01-13 | P3 | Novartis Pharmaceuticals NVS | NCT04720157 An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in A | Prostatic Neoplasms | active not recruiting | 1144 |
| 2025-01-13 | P2 | Celon Pharma SA | NCT05297201 Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia | Parkinson Disease; Dyskinesia, Medication-Induced | completed | 105 |
| 2025-01-13 | P3 | Emalex Biosciences Inc. | NCT05615220 Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults | Tourette Disorder | completed | 216 |
| 2025-01-13 | P2/P3 | Boehringer Ingelheim | NCT05856526 A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome | Netherton Syndrome | terminated | 43 |
| 2025-01-13 | P1/P2 | Evopoint Biosciences Inc. | NCT06022757 Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | Carcinoma; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Prostate Cancer; Small-ce | terminated | 12 |
| 2025-01-13 | P2 | Aardvark Therapeutics, Inc. AARD | NCT06126653 A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Autism Spectrum Disorder | completed | 5 |
| 2025-01-13 | P2 | Bigespas LTD | NCT06292351 DMB-I in the Treatment of Alzheimer Type Dementia | Alzheimer Disease; Dementia of Alzheimer Type | completed | 133 |
| 2025-01-14 | P1/P2 | Sarepta Therapeutics, Inc. SRPT | NCT03652259 Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan | Limb-Girdle Muscular Dystrophy, Type 2E | terminated | 6 |
| 2025-01-14 | P3 | BioMarin Pharmaceutical BMRN | NCT05270837 Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria | Phenylketonuria (PKU) | active not recruiting | 55 |
| 2025-01-14 | P1/P2 | Inmagene LLC | NCT06060977 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants | Alopecia Areata (AA) | completed | 29 |
| 2025-01-14 | P2 | Lexicon Pharmaceuticals LXRX | NCT06203002 A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) | Diabetic Peripheral Neuropathic Pain | completed | 496 |
| 2025-01-14 | P3 | Janssen Pharmaceutical K.K. | NCT06295692 A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | active not recruiting | 19 |
| 2025-01-14 | P3 | Avexima Diol LLC | NCT07124819 Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin | Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Venous Thromboembolism (VTE); Preve | completed | 215 |
| 2025-01-15 | P2 | Gilead Sciences GILD | NCT03964727 Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Metastatic Solid Tumor | active not recruiting | 227 |
| 2025-01-15 | P3 | Hoffmann-La Roche | NCT04035005 A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | active not recruiting | 1013 |
| 2025-01-15 | P3 | Saving Patients' Lives Medical B.V. | NCT04261777 Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | Prostate Cancer; Metastasis; Prostatectomy | terminated | 172 |
| 2025-01-15 | P3 | Principia Biopharma, a Sanofi Company | NCT04562766 Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia | completed | 232 |
| 2025-01-15 | P2 | Miltenyi Biomedicine GmbH | NCT04844866 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Diffuse Large B-cell Lymphoma | recruiting | 213 |
| 2025-01-15 | P3 | Mylan Technologies Inc. | NCT05139121 Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles | Contraception | completed | 1320 |
| 2025-01-15 | P2 | Eli Lilly and Company LLY | NCT05440786 CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | Sarcoma, Ewing; Neoplasm Metastasis | active not recruiting | 46 |
| 2025-01-15 | P1/P2 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | NCT05580770 Mirdametinib + BGB-3245 in Advanced Solid Tumors | Advanced Solid Tumor | terminated | 23 |
| 2025-01-15 | P3 | GlaxoSmithKline | NCT05705440 A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies D | Respiratory Syncytial Virus Infections | completed | 3855 |
| 2025-01-15 | P2 | Mineralys Therapeutics Inc. MLYS | NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen | Hypertension | completed | 285 |
| 2025-01-15 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05849727 A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis | Rheumatoid Arthritis | terminated | 195 |
| 2025-01-15 | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06419582 BHV-7000 Acute Treatment of Bipolar Mania | Bipolar Disorder | completed | 274 |
| 2025-01-15 | P2 | TAHO Pharmaceuticals Ltd. | NCT06689436 Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers | Random Allocation; Intermittent Fasting; Enteral Feeding | completed | 60 |
| 2025-01-16 | P2 | Gilead Sciences GILD | NCT05281510 Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women | HIV-1-infection | completed | 20 |
| 2025-01-16 | P3 | Novo Nordisk A/S NVO | NCT05890976 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Overweight; Obesity | completed | 200 |
| 2025-01-16 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06527144 A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Pulmonary Disease, Chronic Obstructive | completed | 240 |
| 2025-01-16 | P1/P2 | Beijing Mabworks Biotech Co., Ltd. | NCT07044115 Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis | Lupus Nephritis | active not recruiting | 41 |
| 2025-01-17 | P1/P2 | Great Novel Therapeutics Biotech & Medicals Corporation | NCT05770882 Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma (HCC) | terminated | 7 |
| 2025-01-17 | P3 | Novo Nordisk A/S NVO | NCT05813925 A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight | Obesity or Overweight | completed | 331 |
| 2025-01-17 | P3 | Kowa Research Institute, Inc. | NCT05826353 A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial | Fuchs Endothelial Corneal Dystrophy | completed | 110 |
| 2025-01-17 | P3 | Ferring Pharmaceuticals | NCT05831189 A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides | Clostridium Difficile Infection Recurrence | completed | 41 |
| 2025-01-17 est. | P1/P2 | Shanton Pharma Pte. Ltd. | NCT06729853 PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function | Gout; Hyperuricemia | active not recruiting | 32 |
| 2025-01-20 | P2 | Novartis Pharmaceuticals NVS | NCT04952753 Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | Metastatic Colorectal Cancer | terminated | 202 |
| 2025-01-20 | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT05279768 Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. | Polycystic Ovary Syndrome | completed | 44 |
| 2025-01-20 | P3 | Supernus Pharmaceuticals, Inc. SUPN | NCT05655520 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | Huntington's Disease | terminated | 153 |
| 2025-01-20 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT05847920 Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy | Primary IgA Nephropathy | terminated | 53 |
| 2025-01-20 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06531707 Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine | Common Cold | completed | 177 |
| 2025-01-21 | P3 | Chiesi Farmaceutici S.p.A. | NCT03566017 Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease | Fabry Disease | completed | 97 |
| 2025-01-21 | P2 | Genentech, Inc. | NCT03815058 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With | Advanced Melanoma | completed | 131 |
| 2025-01-21 | P2 | Navitor Pharmaceuticals, Inc. | NCT05066672 Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression | Treatment Resistant Depression | completed | 250 |
| 2025-01-21 | P2 | Rivus Pharmaceuticals, Inc. | NCT05979779 Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Fatty Liver | active not recruiting | 219 |
| 2025-01-21 | P2 | Unity Biotechnology, Inc. | NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) | Diabetic Macular Edema; Retinal Disease; Macular Edema; Diabetes Mellitus; Diabetic Retinopathy; Ret | completed | 52 |
| 2025-01-21 | P1/P2 | Wuhan YZY Biopharma Co., Ltd. | NCT06266143 A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | Advanced Pancreatic Adenocarcinoma | completed | 71 |
| 2025-01-21 | P1/P2 | Sutro Biopharma, Inc. STRO | NCT06679582 Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | Acute Myeloid Leukemia (AML) | terminated | 1 |
| 2025-01-22 | P3 | Ethicon, Inc. | NCT03255174 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study | Controlling Mild to Moderate Bleeding During Surgery | completed | 35 |
| 2025-01-22 | P1/P2 | Xantho Biotechnology Co., LTD | NCT04369846 A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients | Atopic Dermatitis | completed | 76 |
| 2025-01-22 | P3 | Novartis Pharmaceuticals NVS | NCT04940052 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V6 | Differentiated Thyroid Cancer (DTC) | active not recruiting | 153 |
| 2025-01-22 | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT04944706 Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction | Chronic Heart Failure With Preserved Ejection Fraction | completed | 225 |
| 2025-01-22 | P2 | Lumos Pharma | NCT05250063 Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) | Growth Hormone Deficiency | completed | 15 |
| 2025-01-22 | P2 | Eli Lilly and Company LLY | NCT05592275 A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure; Heart Failure With Preserved Ejection Fraction | terminated | 332 |
| 2025-01-22 | P2 | 10xBio, LLC | NCT05760248 Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity | Subcutaneous Fat Disorder | completed | 13 |
| 2025-01-22 | P3 | Takeda TAK | NCT06088043 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment | Plaque Psoriasis | completed | 693 |
| 2025-01-22 | P2 | Eli Lilly and Company LLY | NCT06124807 A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity; Overweight and Obesity | completed | 179 |
| 2025-01-22 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06250946 Efficacy and Safety of HRS-7535 Tablets in Obese Subjects . | Overweight and Obesity | completed | 235 |
| 2025-01-23 | P3 | EMS | NCT03540355 Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment | Dyslipidemias | completed | 406 |
| 2025-01-23 | P2 | Ironwood Pharmaceuticals, Inc. IRWD | NCT05740007 A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis; Bladder Pain Syndrome | terminated | 98 |
| 2025-01-23 | P1/P2 | STCube, Inc. | NCT06016270 A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | terminated | 10 |
| 2025-01-23 | P3 | Keymed Biosciences Co.Ltd | NCT06277765 Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis | Atopic Dermatitis | completed | 180 |
| 2025-01-23 | P3 | Tonghua Dongbao Pharmaceutical Co.,Ltd | NCT07282054 Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes | Type 1 Diabetes | completed | 550 |
| 2025-01-24 | P1/P2 | Clarity Pharmaceuticals Ltd | NCT04023331 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | Neuroblastoma; Relapsed Neuroblastoma; Refractory Neuroblastoma | terminated | 21 |
| 2025-01-24 | P2 | Ionis Pharmaceuticals, Inc. IONS | NCT04307381 An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema | Hereditary Angioedema | completed | 20 |
| 2025-01-24 | P2 | BeiGene | NCT05479994 Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia; Lymphoma; Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lympho | active not recruiting | 100 |
| 2025-01-24 | P1/P2 | Centessa Pharmaceuticals (UK) Limited | NCT05821777 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | terminated | 25 |
| 2025-01-24 est. | P3 | Novo Nordisk A/S NVO | NCT06083675 Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | withdrawn | |
| 2025-01-24 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07442877 A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Postoperative Pain Management | completed | 161 |
| 2025-01-25 | P2 | Mina Alpha Limited | NCT04710641 Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone | Hepatocellular Carcinoma; Hepatitis B; Hepatitis C | completed | 8 |
| 2025-01-26 | P2 | Bridge Biotherapeutics, Inc. | NCT05483907 To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF | Idiopathic Pulmonary Fibrosis | completed | 129 |
| 2025-01-27 | P3 | AstraZeneca AZN | NCT03534453 Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Plat | completed | 225 |
| 2025-01-27 | P1/P2 | Loxo Oncology, Inc. | NCT03740529 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lym | completed | 803 |
| 2025-01-27 | P3 | Hoffmann-La Roche | NCT04222972 A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tr | terminated | 223 |
| 2025-01-27 | P2 | Merck Sharp & Dohme LLC MRK | NCT04704219 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) | Renal Cell Carcinoma | completed | 160 |
| 2025-01-27 | P2 | Bristol-Myers Squibb BMY | NCT05197426 A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Particip | Acute Myeloid Leukemia | active not recruiting | 19 |
| 2025-01-27 | P2 | Neurocrine Biosciences NBIX | NCT05301894 Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep | Epileptic Encephalopathy; Continuous Spike and Wave During Sleep | terminated | 19 |
| 2025-01-27 | P2 | Kite, A Gilead Company | NCT05537766 Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Relapsed/Refractory Waldenstrom Macroglobulinemia; Relapsed/Refractory Richter Transformation; Relap | terminated | 19 |
| 2025-01-27 | P3 | Spero Therapeutics SPRO | NCT06059846 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection | Urinary Tract Infection; Acute Pyelonephritis | completed | 1690 |
| 2025-01-27 | P3 | Jiaxing AnDiCon Biotech Co.,Ltd | NCT06507813 Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza | Influenza Type A; Influenza Type B | completed | 190 |
| 2025-01-27 | P3 | Alcon Research ALC | NCT06538662 An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations | Ocular Redness; Eye Irritation | completed | 284 |
| 2025-01-27 | P2 | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | NCT06575478 Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients | Diabetes Mellitus, Type 2; Diabetes; Type2diabetes | completed | 95 |
| 2025-01-28 | P3 | Zealand Pharma ZEAL.CO | NCT03941236 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism | Congenital Hyperinsulinism | completed | 42 |
| 2025-01-28 | P2 | Sermonix Pharmaceuticals Inc. | NCT04432454 Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Metastatic Breast Cancer | completed | 29 |
| 2025-01-28 | P3 | Jazz Pharmaceuticals JAZZ | NCT04485104 Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndr | Seizure in Participants With Tuberous Sclerosis Complex; Seizure in Participants With Dravet Syndrom | terminated | 3 |
| 2025-01-28 | P3 | Novartis Pharmaceuticals NVS | NCT05305664 A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients Wi | Hyperlipoproteinemia(a) | completed | 51 |
| 2025-01-28 | P3 | Novo Nordisk A/S NVO | NCT05394519 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Overweight; Obesity; Type 2 Diabetes Mellitus | completed | 1200 |
| 2025-01-28 | P1/P2 | Advagene Biopharma Co. Ltd. | NCT05985694 AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma | Eosinophilic Asthma | completed | 40 |
| 2025-01-28 | P3 | UCB Biopharma SRL | NCT06471361 A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 31 |
| 2025-01-28 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06641180 Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age | Influenza | completed | 1180 |
| 2025-01-29 | P2 | Xynomic Pharmaceuticals, Inc. | NCT03934567 A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | Lymphoma, Follicular | active not recruiting | 87 |
| 2025-01-29 | P3 | AbbVie ABBV | NCT04468984 Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participant | Myelofibrosis (MF) | active not recruiting | 330 |
| 2025-01-29 | P1/P2 | OnKure, Inc. OKUR | NCT05340621 NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | RAS Mutation; NRAS Gene Mutation; Melanoma | completed | 36 |
| 2025-01-29 | P3 | Amgen AMGN | NCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer (SCLC) | active not recruiting | 509 |
| 2025-01-29 | P3 | ApcinteX Ltd | NCT06568302 The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial | Hemophilia a; Hemophilia B; Hemophilia a with Inhibitor; Hemophilia B with Inhibitor | terminated | 15 |
| 2025-01-30 | P2/P3 | Pharming Technologies B.V. PHAR | NCT02859727 Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI | Activated PI3Kdelta Syndrome (APDS); PASLI Disease | terminated | 37 |
| 2025-01-30 | P3 | Baxalta now part of Shire | NCT03879135 A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) | Von Willebrand Disease (VWD) | completed | 38 |
| 2025-01-30 | P2 | Merck Sharp & Dohme LLC MRK | NCT04564547 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Ty | HIV-1 Infection | completed | 161 |
| 2025-01-30 | P2 | Hoffmann-La Roche | NCT04785820 A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of th | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | completed | 190 |
| 2025-01-30 | P2 | Adaptive Phage Therapeutics, Inc. | NCT05177107 Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis | Osteomyelitis; Diabetic Foot Osteomyelitis | terminated | 41 |
| 2025-01-30 est. | P1/P2 | Inmunotek S.L. | NCT05208060 Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells | Immune Response | unknown | 48 |
| 2025-01-30 | P3 | RDC Clinical Pty Ltd | NCT05795816 Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms | Long Covid19 | completed | 150 |
| 2025-01-30 | P2/P3 | Atom Therapeutics Co., Ltd | NCT05818085 Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout | Gout | completed | 300 |
| 2025-01-30 | P2 | Cerevance Beta, Inc. | NCT06006247 Early Parkinson's Disease Monotherapy With CVN424 | Parkinson's Disease | completed | 64 |
| 2025-01-30 est. | P2 | Huabo Biopharm Co., Ltd. | NCT06222125 A Study of HB0025 Injection in Patients With Advanced Renal Cancer | Renal Cancer | unknown | 100 |
| 2025-01-30 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06299982 An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO | Plaque Psoriasis Patients | unknown | 750 |
| 2025-01-30 est. | P3 | Akeso | NCT06383468 A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | unknown | 420 |
| 2025-01-30 est. | P2 | DHA Coffee Co., Ltd | NCT06489860 SARS-CoV-2 Safety Study for the Treatment of COVID-19 | SARS-CoV-2 | withdrawn | |
| 2025-01-30 | P3 | Alcon Research ALC | NCT06544707 A Study Designed to Evaluate Tear Production | Dry Eye Disease | completed | 81 |
| 2025-01-30 | P2 | Novartis Pharmaceuticals NVS | NCT07235020 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria | Uncomplicated Plasmodium Falciparum Malaria | completed | 52 |
| 2025-01-31 | P1/P2 | AstraZeneca AZN | NCT04538742 A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer | Metastatic Breast Cancer | active not recruiting | 245 |
| 2025-01-31 est. | P3 | Hoffmann-La Roche | NCT05126966 A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With | Neovascular Age-Related Macular Degeneration | withdrawn | |
| 2025-01-31 | P2 | Spruce Biosciences SPRB | NCT05128942 A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH | Congenital Adrenal Hyperplasia; 21-OHD | terminated | 67 |
| 2025-01-31 | P2 | Cardiol Therapeutics Inc. CRDL | NCT05180240 Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis | Acute Myocarditis | completed | 109 |
| 2025-01-31 | P3 | Cassava Sciences, Inc. | NCT05575076 Open-label Extension for Phase 3 Clinical Trials of Simufilam | Alzheimer Disease | terminated | 1081 |
| 2025-01-31 | P3 | Pfizer PFE | NCT05654623 A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer | Advanced Breast Cancer | active not recruiting | 624 |
| 2025-01-31 est. | P2 | Ascension Health | NCT05691959 Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response | Atrial Fibrillation With Rapid Ventricular Response; Hypotension | unknown | 378 |
| 2025-01-31 | P2 | BioCryst Pharmaceuticals BCRX | NCT05741346 Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | terminated | 28 |
| 2025-01-31 | P2 | Alector Inc. ALEC | NCT05744401 A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease | Alzheimer's Disease | terminated | 197 |
| 2025-01-31 | P3 | Intuitive Surgical ISRG | NCT05954767 IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery | Ureter Injury | completed | 189 |
| 2025-01-31 | P2 | Inspirna, Inc. | NCT05983367 A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | Colorectal Cancer; Metastatic Colon Cancer | terminated | 76 |
| 2025-01-31 est. | P2 | Monyan Pharmaceutical (Shanghai) Co., Ltd. | NCT06092606 A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients | Cancer; Heart Failure; Arrhythmia; Doxorubicin Induced Cardiomyopathy; Doxorubicin Adverse Reaction | unknown | 90 |
| 2025-01-31 | P1/P2 | SpyGlass Pharma, Inc. SGP | NCT06120842 Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution | Cataract; Glaucoma; Ocular Hypertension | active not recruiting | 201 |
| 2025-01-31 est. | P1/P2 | Hobart W. Harris | NCT06134843 Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds | Skin Graft Complications | unknown | 12 |
| 2025-01-31 est. | P2 | RemeGen Co., Ltd. | NCT06155383 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2025-01-31 | P3 | Viatris Specialty LLC VTRS | NCT06215859 Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy | Acute Pain; Post Operative Pain; Pain | completed | 579 |
| 2025-01-31 est. | P3 | Pharming Technologies B.V. PHAR | NCT06249997 An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS | APDS Gene Mutation | unknown | 3 |
| 2025-01-31 | P3 | Tris Pharma, Inc. | NCT06423703 A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy | Acute Pain | completed | 240 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.